我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
25
3 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
12
48.0%
尚未招募
3
12.0%
招募中
5
20.0%
Unknown
暂无批准数据
- A randomized, double-blind, placebo-controlled crossover trial in 30 healthy adults found a single 500-mg dose of the yeast-derived postbiotic EpiCor rapidly modulated inflammatory cytokines within 1–3 hours. - IFN-γ and IL-1ra fell significantly at 1 hour, while IL-4, IL-7, and IL-8 declined significantly at 2 hours, with downward trends for IL-1β, IL-5, and TNF-α. - The changes reflected targeted modulation of specific inflammatory pathways rather than broad immune suppression, accompanied by transient redistribution of CD25-positive immune cell subsets. - Researchers hypothesize the rapid response may involve gut–brain neuroimmune and vagal signaling, though the mechanism remains unproven and requires further study.